PLUS1
36.50
-1.55 (-4.07%)
-1.55 (-4.07%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | YMAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.55 | -4.07% | 36.50 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 38.07 | 34.50 | 38.725 | 36.50 | 38.05 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 33.67 | 51.96 | 18.29 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,738 | 712,612 | $ 36.92 | $ 26,306,795 | 240,221 | 14.16 - 55.36 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:33:13 | formt | 3,700 | $ 36.50 | USD |
Y mAbs Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.48B | 40.51M | 30.41M | $ - | $ - | -2.31 | -14.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -72.30k | 1.10% |
Y mAbs Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/22/2021 | 16:16 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/22/2021 | 16:01 | GlobeNewswire Inc. | Y-mAbs Therapeutics, Inc. Announces Closing of Public.. |
| 2/19/2021 | 09:00 | GlobeNewswire Inc. | Y-mAbs to Announce 2020 Financial and Operating Results on.. |
| 2/18/2021 | 16:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/18/2021 | 00:50 | Seeking Alpha | Y-mAbs prices equity offering at $41 |
| 2/17/2021 | 19:14 | GlobeNewswire Inc. | Y-mAbs Announces Pricing of Public Offering of Common Stock |
| 2/17/2021 | 06:08 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical YMAB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 44.92 | 46.11 | 34.50 | 41.13 | 466,440 | -8.42 | -18.74% |
| 1 Month | 43.12 | 50.70 | 34.50 | 43.02 | 257,513 | -6.62 | -15.35% |
| 3 Months | 52.03 | 55.00 | 34.50 | 47.60 | 240,558 | -15.53 | -29.85% |
| 6 Months | 42.69 | 55.36 | 34.50 | 45.18 | 201,844 | -6.19 | -14.5% |
| 1 Year | 31.64 | 55.36 | 14.16 | 39.54 | 215,862 | 4.86 | 15.36% |
| 3 Years | 26.50 | 55.36 | 14.16 | 32.94 | 183,239 | 10.00 | 37.74% |
| 5 Years | 26.50 | 55.36 | 14.16 | 32.94 | 183,239 | 10.00 | 37.74% |
Y mAbs Therapeutics Description
| Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system. |
